Show simple item record

dc.contributor.authorWillumsen, Johannes Sverre
dc.contributor.authorGrytten, Nina
dc.contributor.authorAarseth, Jan Harald
dc.contributor.authorMyklebust, Tor Åge
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorMidgard, Rune
dc.date.accessioned2023-01-10T13:26:44Z
dc.date.available2023-01-10T13:26:44Z
dc.date.created2022-12-01T12:30:21Z
dc.date.issued2022
dc.identifier.issn0022-3050
dc.identifier.urihttps://hdl.handle.net/11250/3042385
dc.description.abstractBackground Persons with multiple sclerosis (pwMS) have higher risk of mortality compared with the general population. Longitudinal studies are important for understanding the evolution of survival in pwMS. Objective Examine changes in mortality among pwMS during the past seven decades. Methods We followed pwMS from Hordaland and Møre and Romsdal in Western Norway, with disease onset from before 1950, identified from population-based epidemiological surveys and the Norwegian MS Registry and Biobank, until 1 January 2021. Data were linked to the Norwegian Cause of Death Registry to obtain underlying cause of death. We examined all-cause, and cause-specific mortality using standardised mortality ratios (SMR) and excess death rates (EDR). We calculated life expectancies and assessed survival stratified by sex, age and disease phenotype at onset. We compared hazard ratios (HRs) for mortality, in pwMS diagnosed before and after the era of disease-modifying treatment (DMT). Results Of 3624 pwMS, 964 (55.5% women) had died, predominantly of multiple sclerosis (49.0%). Median life expectancy for pwMS was 74.3 years (95% CI 73.3 to 75.3), compared with 83.1 years for the general population (p<0.001). From disease onset, pwMS survived 14.6 years shorter than the general population (p<0.001). Overall, SMR was 2.3 (95% CI 2.13 to 2.42) and EDR was 6.8 (95% CI 6.42 to 7.09) for pwMS. Treatment-eligible pwMS diagnosed in the DMT era had the lowest risk of mortality, HR 0.49 (95% CI 0.34 to 0.70,p<0.001). Conclusion Excess mortality among pwMS declined during the past seven decades, possibly due to improved diagnostics, better symptomatic treatment and access to DMTs.en_US
dc.language.isoengen_US
dc.publisherBMJen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleMortality and cause of death in multiple sclerosis in western Norway 1950-2021: A registry-based linkage studyen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1136/jnnp-2022-329169
dc.identifier.cristin2086992
dc.source.journalJournal of Neurology, Neurosurgery and Psychiatryen_US
dc.source.pagenumber1154-1161en_US
dc.identifier.citationJournal of Neurology, Neurosurgery and Psychiatry. 2022, 93 (11), 1154-1161.en_US
dc.source.volume93en_US
dc.source.issue11en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal